"Benzazepines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with BENZENE fused to AZEPINES.
| Descriptor ID |
D001552
|
| MeSH Number(s) |
D03.633.100.079
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzazepines".
Below are MeSH descriptors whose meaning is more specific than "Benzazepines".
This graph shows the total number of publications written about "Benzazepines" by people in this website by year, and whether "Benzazepines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 3 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 4 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 4 | 1 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 5 | 7 |
| 2011 | 4 | 1 | 5 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 5 | 0 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzazepines" by people in Profiles.
-
Lysine demethylase KDM6B regulates HIF-1a-mediated systemic and cellular responses to intermittent hypoxia. Physiol Genomics. 2021 09 01; 53(9):385-394.
-
5-HT2c agonist, lorcaserin, reduces aggressive responding in intermittent explosive disorder: A pilot study. Hum Psychopharmacol. 2019 11; 34(6):e2714.
-
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588.
-
Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
-
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 03 01; 33(3):477-489.
-
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
-
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
-
The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017 Oct 03; 70(14):1777-1784.
-
Operant responding for optogenetic excitation of LDTg inputs to the VTA requires D1 and D2 dopamine receptor activation in the NAcc. Behav Brain Res. 2017 08 30; 333:161-170.
-
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975.